acePrognostic risk modeling based on integrated multi-omics analysis identifies CRY2 as a key regulator in tumor immunity and patient survival in colorectal cancer
Colorectal cancer (CRC) exhibits substantial metabolic heterogeneity. This study developed a robust prognostic signature integrating ferroptosis- and lipid metabolism-related genes to investigate the role of CRY2 in CRC progression. Transcriptomic and clinical data from the TCGA-COAD and GSE39582 cohorts were analyzed. Weighted gene co-expression network analysis (WGCNA) was performed to identify disease-associated gene modules. A machine learning framework was subsequently applied to construct and optimize the…
"25.5.2012 Seminario 'Medidas sociales y políticas sobre la familia' / 5.25.2012 Panel Session 'Family Social and Government Policies'" by HazteOir.org is licensed under CC BY-SA 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by-sa/2.0/.
On 2026-08-04, a peer-reviewed study reported development of a ferroptosis- and lipid metabolism-related prognostic signature for colorectal cancer using transcriptomic data from TCGA-COAD and GSE39582, WGCNA, and a machine learning pipeline of forward stepwise Cox regression combined with Random Survival Forest. The RiskScore was an independent predictor of overall survival and stratified immune features, and CRY2 emerged as a key signature gene validated by knockdown experiments.
The work matters because it connects an AI-derived risk model to patient survival and tumor immunity, suggesting a path toward more precise prognosis and a potential therapeutic target in CRY2, with in vitro inhibition of proliferation and migration and in vivo suppression of xenograft growth. What remains uncertain is clinical translation beyond retrospective cohorts and cell-line and mouse models, including safety, efficacy, and generalizability of targeting CRY2 in human patients.
- Analysis used transcriptomic and clinical data from TCGA-COAD and GSE39582 cohorts with WGCNA to identify disease-associated modules.
- High-risk patients showed poorer overall survival and an immunosuppressive TME with increased regulatory T cells and Th2 cells, reduced CD4+ T-cell infiltration, and higher TIDE scores suggesting immunotherapy resistance.
- Functional validation showed CRY2 knockdown inhibited CRC cell proliferation and migration while inducing G1-phase cell-cycle arrest in vitro.
A StepCox plus Random Survival Forest framework built a ferroptosis- and lipid metabolism-related RiskScore that independently predicted overall survival in TCGA-COAD and GSE39582 colorectal cancer cohorts, and identified CRY2 as a regulator whose knockdown inhibited proliferation and suppressed xenograft growth.
The rundown
Researchers integrated ferroptosis- and lipid metabolism-related genes using WGCNA and a machine learning framework, selecting StepCox plus Random Survival Forest as best performing to generate a RiskScore tested in TCGA-COAD and GSE39582.
Immune profiling with CIBERSORT and TIDE linked high-risk status to increased Tregs and Th2 cells, reduced CD4+ T-cell infiltration, and higher TIDE scores, while siRNA knockdown and murine xenograft experiments demonstrated CRY2's role in proliferation, migration, and tumor growth.
Sources
- Peer-reviewedAnnals of Medicine2026-08-04
How should this claim be treated?
The debate